ANKRD26 and cancer: Eight genes were included in the study- ANKRD26, CEBPA, DDX41, ETV6, GATA2, MECOM, RUNX1, and SRP72. ANKRD26, GATA2, DDX41, CEBPA and RUNX1 are well-established myeloid malignancy predisposition genes, but the population prevalence is unknown since prior studies included cohorts ascertained on phenotype such as cancer registries or clinically identified cases series.